## Mar Riveiro-Barciela

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2064230/publications.pdf

Version: 2024-02-01

71 papers

2,888 citations

393982 19 h-index 50 g-index

75 all docs

75 docs citations

75 times ranked 7200 citing authors

#	Article	IF	CITATIONS
1	Genomewide Association Study of Severe Covid-19 with Respiratory Failure. New England Journal of Medicine, 2020, 383, 1522-1534.	13.9	1,548
2	Factors Associated With Rates of HBsAg Seroclearance in Adults With Chronic HBV Infection: A Systematic Review and Meta-analysis. Gastroenterology, 2019, 156, 635-646.e9.	0.6	162
3	Phylogenetic Demonstration of Hepatitis E Infection Transmitted by Pork Meat Ingestion. Journal of Clinical Gastroenterology, 2015, 49, 165-168.	1.1	80
4	Efficacy of Sofosbuvir and Velpatasvir, With and Without Ribavirin, in Patients With Hepatitis C Virus Genotype 3ÂlnfectionÂand Cirrhosis. Gastroenterology, 2018, 155, 1120-1127.e4.	0.6	76
5	Management of direct-acting antiviral agent failures. Journal of Hepatology, 2015, 63, 1511-1522.	1.8	73
6	Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs. Journal of Hepatology, 2019, 71, 666-672.	1.8	67
7	Effectiveness and Safety of Entecavir or Tenofovir in a Spanish Cohort of Chronic Hepatitis B Patients: Validation of the Page-B Score to Predict Hepatocellular Carcinoma. Digestive Diseases and Sciences, 2017, 62, 784-793.	1.1	55
8	Longâ€ŧerm clinical outcomes in patients with chronic hepatitis delta: the role of persistent viraemia. Alimentary Pharmacology and Therapeutics, 2020, 51, 158-166.	1.9	49
9	Detailed stratified GWAS analysis for severe COVID-19 in four European populations. Human Molecular Genetics, 2022, 31, 3945-3966.	1.4	46
10	Rapid liver and spleen stiffness improvement in compensated advanced chronic liver disease patients treated with oral antivirals. Therapeutic Advances in Gastroenterology, 2017, 10, 619-629.	1.4	45
11	Acute liver failure due to immune-mediated hepatitis successfully managed with plasma exchange: New settings call for new treatment strategies?. Journal of Hepatology, 2019, 70, 564-566.	1.8	45
12	Immuneâ€related hepatitis related to checkpoint inhibitors: Clinical and prognostic factors. Liver International, 2020, 40, 1906-1916.	1.9	43
13	Red blood cell transfusionâ€transmitted acute hepatitis E in an immunocompetent subject in Europe: a case report. Transfusion, 2017, 57, 244-247.	0.8	41
14	Incidences and Determinants of Functional Cure During Entecavir or Tenofovir Disoproxil Fumarate for Chronic Hepatitis B. Journal of Infectious Diseases, 2021, 224, 1890-1899.	1.9	40
15	Deep-sequencing reveals broad subtype-specific HCV resistance mutations associated with treatment failure. Antiviral Research, 2020, 174, 104694.	1.9	39
16	Longâ€ŧerm safety and efficacy of nucleo(t)side analogue therapy in hepatitis B. Liver International, 2018, 38, 84-89.	1.9	38
17	Hepatitis B Core-Related Antigen to Indicate High Viral Load: Systematic Review and Meta-Analysis of 10,397 Individual Participants. Clinical Gastroenterology and Hepatology, 2021, 19, 46-60.e8.	2.4	27
18	Unexpected longâ€lasting antiâ€HEV IgM positivity: Is HEV antigen a better serological marker for hepatitis E infection diagnosis?. Journal of Viral Hepatitis, 2020, 27, 747-753.	1.0	26

#	Article	IF	CITATIONS
19	Oneâ€quarter of chronic hepatitis D patients reach HDVâ€RNA decline or undetectability during the natural course of the disease. Alimentary Pharmacology and Therapeutics, 2021, 54, 462-469.	1.9	25
20	Tenofovir Alafenamide Fumarate: A New Tenofovir Prodrug for the Treatment of Chronic Hepatitis B Infection. Journal of Infectious Diseases, 2017, 216, S792-S796.	1.9	21
21	Evidence of an Exponential Decay Pattern of the Hepatitis Delta Virus Evolution Rate and Fluctuations in Quasispecies Complexity in Long-Term Studies of Chronic Delta Infection. PLoS ONE, 2016, 11, e0158557.	1.1	19
22	Retreatment With Immune Checkpoint Inhibitors After a Severe Immune-Related Hepatitis: Results From a Prospective Multicenter Study. Clinical Gastroenterology and Hepatology, 2023, 21, 732-740.	2.4	19
23	Reflex viral load testing in dried blood spots generated by plasma separation card allows the screening and diagnosis of chronic viral hepatitis. Journal of Virological Methods, 2021, 289, 114039.	1.0	17
24	Assessing Liver Fibrosis Using the FIB4 Index in the Community Setting. Diagnostics, 2021, 11, 2236.	1.3	16
25	Tenofovir discontinuation after long-term viral suppression in HBeAg negative chronic hepatitis B. Can HBsAg levels be useful?. Journal of Clinical Virology, 2015, 68, 61-68.	1.6	15
26	Differential characteristics and outcomes of Asian and nonâ€Asian patients with HBVâ€related hepatocellular carcinoma. Liver International, 2021, 41, 1922-1932.	1.9	15
27	Thrombotic thrombocytopenic purpura relapse induced by acute hepatitis E transmitted by cryosupernatant plasma and successfully controlled with ribavirin. Transfusion, 2018, 58, 2501-2505.	0.8	14
28	Role of Biomarkers in Guiding Cure of Viral Hepatitis B. Seminars in Liver Disease, 2020, 40, 049-060.	1.8	13
29	Optimal management of chronic hepatitis B patients receiving nucleos(t)ide analogues. Liver International, 2020, 40, 15-21.	1.9	13
30	Etiologies and Features of Acute Viral Hepatitis in Spain. Clinical Gastroenterology and Hepatology, 2021, 19, 1030-1037.	2.4	12
31	Quantitative characterization of hepatitis delta virus genome edition by next-generation sequencing. Virus Research, 2018, 243, 52-59.	1.1	11
32	An electronic alert system increases screening for hepatitis B and C and improves management of patients with haematological disorders. Scientific Reports, 2020, 10, 3038.	1.6	11
33	Cancer immunotherapy in special challenging populations: recommendations of the Advisory Committee of Spanish Melanoma Group (GEM)., 2021, 9, e001664.		11
34	Hepatic sinusoidal obstruction syndrome associated with nivolumab: an uncommon adverse event related to immune checkpoint inhibitors. Journal of Gastrointestinal and Liver Diseases, 2021, 30, 171-172.	0.5	11
35	Hepatitis E virus: new faces of an old infection. Annals of Hepatology, 2013, 12, 861-70.	0.6	11
36	Simple predictive models identify patients with COVID-19 pneumonia and poor prognosis. PLoS ONE, 2020, 15, e0244627.	1.1	9

#	Article	IF	CITATIONS
37	Effect of Hepatitis E Virus RNA Universal Blood Donor Screening, Catalonia, Spain, 2017â€'2020. Emerging Infectious Diseases, 2022, 28, 157-165.	2.0	9
38	Early predictors of corticosteroid response in acute severe autoimmune hepatitis: a nationwide multicenter study. Alimentary Pharmacology and Therapeutics, 2022, 56, 131-143.	1.9	9
39	Chronic hepatitis D associated with worse patient-reported outcomes than chronic hepatitis B. JHEP Reports, 2021, 3, 100280.	2.6	8
40	Toxicities from immunotherapy: From clinical trials to real-world clinical practice. Medicina ClÃnica, 2020, 155, 541-547.	0.3	8
41	Conservation and variability of hepatitis B core at different chronic hepatitis stages. World Journal of Gastroenterology, 2020, 26, 2584-2598.	1.4	8
42	A 79-Year-Old Man With Dyspnea, Dysphagia, and Weakness. Chest, 2012, 142, 252-255.	0.4	7
43	Application of EASL 2017 criteria for switching hepatitis B patients from tenofovir disoproxil to entecavir or tenofovir alafenamide. Digestive and Liver Disease, 2020, 52, 1164-1169.	0.4	7
44	The role of liver steatosis as measured with transient elastography and transaminases on hard clinical outcomes in patients with COVID-19. Therapeutic Advances in Gastroenterology, 2021, 14, 175628482110165.	1.4	7
45	Characterization of hepatitis B virus X gene quasispecies complexity in mono-infection and hepatitis delta virus superinfection. World Journal of Gastroenterology, 2019, 25, 1566-1579.	1.4	7
46	Costâ€effectiveness analysis of an active search to retrieve <scp>HCV</scp> patients lost to followâ€up ( <scp>RELINK </scp> strategy) and the impact of <scp>COVID</scp> â€19. Journal of Viral Hepatitis, 2022, 29, 579-583.	1.0	7
47	Inferior Cava Vein Syndrome and Heart Compression Due to a Giant Liver Cyst. American Journal of Gastroenterology, 2017, 112, 984.	0.2	5
48	$Na\tilde{A}^-$ ve hepatitis B e antigen-negative chronic hepatitis B patients are at risk of carotid atherosclerosis: A prospective study. World Journal of Gastroenterology, 2021, 27, 5112-5125.	1.4	5
49	Treatment of Chronic Hepatitis B Virus with Oral Anti-Viral Therapy. Clinics in Liver Disease, 2021, 25, 725-740.	1.0	5
50	Noninvasive Prediction of Outcomes in Autoimmune Hepatitis–Related Cirrhosis. Hepatology Communications, 2022, 6, 1392-1402.	2.0	5
51	Sclerosing Cholangitis Related to IgG4: Not Always a Curable Entity. Annals of Hepatology, 2019, 18, 215-219.	0.6	4
52	Inspecting the Ribozyme Region of Hepatitis Delta Virus Genotype 1: Conservation and Variability. Viruses, 2022, 14, 215.	1.5	4
53	Gallstone ileus secondary to a cholecystocolonic fistula. GastroenterologÃa Y HepatologÃa, 2018, 41, 510-511.	0.2	3
54	Sophisticated viral quasispecies with a genotype-related pattern of mutations in the hepatitis B X gene of HBeAg-ve chronically infected patients. Scientific Reports, 2021, 11, 4215.	1.6	3

#	Article	IF	Citations
55	The Low Incidence of Viral Hepatitis Reactivation Among Subjects on Immunotherapy Reduces the Impact of Suboptimal Screening Rate. Frontiers in Medicine, 0, 9, .	1.2	3
56	Decompensated Liver Disease due to Primary Hepatic Amyloidosis: Is Liver Transplantation Still Mandatory?. Hepatology, 2019, 69, 2701-2703.	3 <b>.</b> 6	2
57	Standardized Hepatitis B Virus RNA Quantification in Untreated and Treated Chronic Patients: a Promising Marker of Infection Follow-Up. Microbiology Spectrum, 2022, 10, e0214921.	1,2	2
58	Palmoplantar pustulosis and chest pain. Lancet, The, 2012, 379, e49.	<b>6.</b> 3	1
59	Outcome and risk of de novo Hepatitis B after liver transplantation: Are all anti-HBc-positive grafts the same?. Clinics and Research in Hepatology and Gastroenterology, 2020, 44, 791-793.	0.7	1
60	Editorial: rapid disease progression in hepatitis deltaâ€"can we turn the tide? Authors' reply. Alimentary Pharmacology and Therapeutics, 2020, 51, 174-175.	1.9	1
61	How to interpret viral markers in the management of chronic hepatitis B infection. Clinical Microbiology and Infection, 2022, 28, 355-361.	2.8	1
62	ACE Score Identifies HBeAg-negative Inactive Carriers at a Single-point Evaluation, Regardless of HBV Genotype. Journal of Clinical and Translational Hepatology, 2022, 000, 000-000.	0.7	1
63	Derrame pleural izquierdo secundario a infartos esplénicos en una paciente con cirrosis hepática. Medicina ClÃnica, 2017, 148, 144-145.	0.3	0
64	Left pleural effusion secondary to splenic infarctions in a patient with liver cirrhosis. Medicina ClÃnica (English Edition), 2017, 148, 144-145.	0.1	0
65	Toxicities from immunotherapy: From clinical trials to real-world clinical practice. Medicina ClÃnica (English Edition), 2020, 155, 541-547.	0.1	0
66	Acquired hepatocerebral degeneration in a metastatic neuroendocrine tumor long-term survivor â€" an update on neuroendocrine neoplasm's treatment: A case report. World Journal of Hepatology, 2021, 13, 611-619.	0.8	0
67	Barriers to linkage to care in hepatitis C patients with substance use disorders and dual diagnoses, despite centralized management. Therapeutic Advances in Gastroenterology, 2021, 14, 175628482110165.	1.4	0
68	Simple predictive models identify patients with COVID-19 pneumonia and poor prognosis., 2020, 15, e0244627.		0
69	Simple predictive models identify patients with COVID-19 pneumonia and poor prognosis., 2020, 15, e0244627.		0
70	Simple predictive models identify patients with COVID-19 pneumonia and poor prognosis., 2020, 15, e0244627.		0
71	Simple predictive models identify patients with COVID-19 pneumonia and poor prognosis. , 2020, 15, e0244627.		0